OnabotulinumtoxinA 100 UNT

ApprovedSmall molecule

OnabotulinumtoxinA 100 UNT is one of 51 small molecule programs targeting Trigeminal Neuralgia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Trigeminal NeuralgiaActive, not recruiting

Overactive BladderActive, not recruiting

Urgency Urinary IncontinenceActive, not recruiting

Trigeminal NeuralgiaApproved

Active, not recruiting

Overactive BladderPhase 3

Active, not recruiting

Urgency Urinary IncontinenceApproved

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Overactive Bladder

#DrugCompanyPhaseTrials

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

3 2

Neurontin

VViatris Specialty LLC

Phase 3

1 3

Botox

AbbVie

Phase 3

3 4

GSK1358820

GSK

Phase 3

1 5

OnabotulinumtoxinA 100 UNT

SStanford University

Approved

1 6

Tolterodine PR

Pfizer

Phase 3

5 7

Oxybutynin Chloride

Mylan Pharmaceuticals Inc

Phase 3

3 8

Vesicare

Astellas

Phase 3

2 9

YM178

Astellas

Phase 3

6 10

SPM 907

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Trigeminal Neuralgia

NCT06216886

Q3 2030

ApprovedActive, not recruiting

Urgency Urinary Incontinence

NCT05806164

Clinical

Trials by Indication[1]

Procedural Pain1 trial

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

Recruiting·UUniversity of South Florida·Phase 4·NCT04305743·60 enrolled

Overactive Bladder1 trial

Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin

Unknown status·UUniversity Of Perugia·Phase 3·NCT03758235·140 enrolled

Botulinum Toxin1 trial

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Completed·UUniversity of California, Irvine·Phase 4·NCT05308979·116 enrolled

Trigeminal Neuralgia1 trial

OnabotulinumtoxinA for Trigeminal Neuralgia

Recruiting·SStanford University·Phase 4·NCT06216886·20 enrolled

Surgery1 trial

BOTOX® at the Time of Prolapse Surgery for OAB

Unknown status·WWalter Reed National Military Medical Center·Phase 4·NCT04807920·138 enrolled

1 more indication

Urgency Urinary Incontinence1 trial

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Active, not recruiting·WWomen and Infants Hospital of Rhode Island·Approved·NCT05806164·432 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for OnabotulinumtoxinA 100 UNT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OnabotulinumtoxinA 100 UNT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OnabotulinumtoxinA 100 UNT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SStanford University

OnabotulinumtoxinA 100 UNT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2030

Trials by Indication[1]

Procedural Pain1 trial

Overactive Bladder1 trial

Botulinum Toxin1 trial

Trigeminal Neuralgia1 trial

Surgery1 trial

Urgency Urinary Incontinence1 trial

References

Drug Info

Quick Facts

Related News